ers of
Regeneration Technologies and Tutogen for their consideration, and
Regeneration Technologies and Tutogen have filed a registration statement,
a joint proxy statement/prospectus and other relevant documents concerning
the proposed transaction with the S.E.C. Shareholders are urged to read the
registration statement and the joint proxy statement/prospectus regarding
the proposed merger and any other relevant documents filed with the S.E.C.,
as well as any amendments or supplements to those documents, because they
contain important information. You can obtain a free copy of the joint
proxy statement/prospectus, as well as other filings containing information
about Regeneration Technologies and Tutogen, at the S.E.C.'s Internet
website (
http://www.sec.gov). You can also obtain these documents, free of
charge, at Regeneration Technologies' website (
http://www.rtix.com) or
Tutogen's website (
http://www.tutogen.com). Copies of the joint proxy
statement/prospectus and the S.E.C. filings that are incorporated by
reference in the joint proxy statement/prospectus can also be obtained,
without charge, by directing a request to Thomas F. Rose, Vice President
and CFO, Regeneration Technologies Inc., P.O. Box 2650, Alachua, Florida
32616 or to L. Robert Johnston, Jr., CFO, Tutogen Medical, Inc., 13709
Progress Blvd., Box 19, Alachua, Florida 32615.
Regeneration Technologies and Tutogen, and their respective directors
and executive officers, may be deemed to be participants in the
solicitation of proxies from the stockholders of Regeneration Technologies
and Tutogen in connection with the proposed merger. Information about the
directors and executive officers of Regeneration Technologies and their
ownership of Regeneration Technologies common stock is set forth in the
proxy statement, dated March 30, 2007, for Regeneration T
'/>"/>
SOURCE Tutogen Medical, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference2.
Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products3.
Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products4.
Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results5.
Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results6.
Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation7.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound8.
QMed, Inc. Reports July Medicare SNP Enrollments9.
Phlo Affiliate Reports Expanded Coverage to Oregon Border10.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results11.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007